All Articles
Showing 181–192 of 223 articles.
FDA Revises Labeling and Monitoring Guidance for GLP-1 Drugs Used in Type 2 Diabetes and Weight Management
FDA Updates Postmarket Safety Monitoring Requirements for GLP-1 Receptor Agonists
Read More →Q&A: Current Uspstf Guidance on PSA-Based Prostate Cancer Screening for Men
Q&A: USPSTF Guidance on PSA-Based Prostate Cancer Screening for Men
Read More →How the FDA Classifies and Reviews Digital Tools for Wellness Tracking
How the FDA Classifies and Reviews Digital Tools for Wellness Tracking
Read More →FDA Outlines Regulatory Framework for AI Tools Used in Preventive Cardiac Monitoring
FDA Outlines Regulatory Framework for AI Tools Used in Preventive Cardiac Monitoring
Read More →What Peer-Reviewed Literature Says About Consumer Wearables and Heart Health Metrics in Male Populations
Recent PMC Studies Evaluate Wearable Devices for Cardiovascular Risk Monitoring in Men
Read More →Large-Scale Analyses Associate Higher Physical Activity Levels with Lower Mortality in Men
Large-Scale Analyses Associate Higher Physical Activity Levels With Lower Mortality in Men
Read More →FDA Mandates Revised Cardiovascular and Prostate Cancer Risk Information in Testosterone Therapy Labeling
FDA Requires Updated Safety Labeling for Testosterone Replacement Therapy Products
Read More →FDA Highlights Post-Approval Cardiovascular and Gastrointestinal Data for Semaglutide
FDA Highlights Post-Approval Cardiovascular and Gastrointestinal Data for Semaglutide
Read More →Q&A: FDA-Authorized Digital Therapeutics for Anxiety and Depression – What the Primary Documents Show
Q&A: FDA-Authorized Digital Therapeutics for Anxiety and Depression – What the Primary Documents Show
Read More →Multiple Independent Cohorts Link Regular Resistance Exercise to Lower Visceral Adiposity and Improved Metabolic Profiles in Men Aged 40–65
Multiple Independent Cohorts Link Regular Resistance Exercise to Lower Visceral Adiposity and Improved Metabolic…
Read More →FDA Revises Labels on GLP-1 Drugs with New Cardiovascular Risk Reduction Information
FDA Revises Labels on GLP-1 Drugs with New Cardiovascular Risk Reduction Information
Read More →CDC Updates Advisory Committee Recommendations for Influenza Vaccination Coverage
CDC Updates Advisory Committee Recommendations for Influenza Vaccination Coverage
Read More →